A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

3期 已完成 NCT03952559

摘要

The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.

Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥2 Point Improvement

Week 16 · Percentage of participants

Open Label Population Pharmacokinetics (Pop PK): Maximum Observed Drug Concentration at Steady State (Cmax,ss) of LY3009104

Predose; 0.25 hours (h); 0.5 h; 1 h; 2-4 h; 4 h and 4-6 h post dose · nanogram per milliliter (ng/mL)

Open Label Pop PK: Area Under the Concentration-Time Curve for Dosing Interval at Steady State (AUCtau,ss) of LY3009104

Predose; 0.25 h; 0.5 h; 1 h; 2-4 h; 4 h and 4-6 h post dose · hour*nanogram per milliliter (h*ng/mL)

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
• Aquacel Hypersensitivity Dressing in TJAs — Rush University Medical Center
• A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Par — Amgen
• A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
• A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic D — Amgen
• BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort — Women's College Hospital

全部试验